These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38399382)

  • 1. Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia.
    Alvarez-Herrera S; Rosel Vales M; Pérez-Sánchez G; Becerril-Villanueva E; Flores-Medina Y; Maldonado-García JL; Saracco-Alvarez R; Escamilla R; Pavón L
    Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A positron emission tomography occupancy study of brexpiprazole at dopamine D
    Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
    Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Dopamine D
    Wysokiński A; Kozłowska E; Szczepocka E; Łucka A; Agier J; Brzezińska-Błaszczyk E; Sobierajska K
    Front Psychiatry; 2021; 12():645081. PubMed ID: 33776821
    [No Abstract]   [Full Text] [Related]  

  • 4. Risperidone in the treatment of schizophrenia.
    Bravo-Mehmedbasic A
    Med Arh; 2011; 65(6):345-7. PubMed ID: 22299296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of prefrontal cortical 5-HT
    Mitazaki S; Nakagawasai O; Onogi H; Watanabe K; Takahashi K; Tan-No K; Quirion R; Srivastava LK; Tadano T
    Behav Brain Res; 2020 Jan; 377():112226. PubMed ID: 31521737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin 5-HT
    Gener T; Tauste Campo A; Alemany-González M; Nebot P; Delgado-Sallent C; Chanovas J; Puig MV
    Neuropharmacology; 2019 Nov; 158():107743. PubMed ID: 31430459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
    Chaki S; Funakoshi T; Yoshikawa R; Okuyama S; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    Neuropharmacology; 1999 Aug; 38(8):1185-94. PubMed ID: 10462131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.
    Taraskina AE; Nasyrova RF; Zabotina AM; Sosin DN; Sosina КА; Ershov EE; Grunina MN; Krupitsky EM
    BMC Psychiatry; 2017 Dec; 17(1):394. PubMed ID: 29221470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
    Li HQ; Xu JY; Gao YY; Jin L
    Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats.
    Conti Mazza MM; Centner A; Werner DF; Bishop C
    Brain Res; 2023 Jul; 1811():148381. PubMed ID: 37127174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.
    Kaur G; Gupta D; Chavan BS; Sinhmar V; Prasad R; Tripathi A; Garg PD; Gupta R; Khurana H; Gautam S; Margoob MA; Aneja J
    Asian J Psychiatr; 2017 Oct; 29():174-182. PubMed ID: 28692863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
    Lane HY; Lee CC; Chang YC; Lu CT; Huang CH; Chang WH
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):461-70. PubMed ID: 15140279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.
    Peñas-Lledó EM; Dorado P; Cáceres MC; de la Rubia A; Llerena A
    Clin Chem Lab Med; 2007; 45(7):835-8. PubMed ID: 17617023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.
    Alladi CG; RajKumar RP; Adithan S; Marie-Claire C; Bellivier F; Shewade DG
    Fundam Clin Pharmacol; 2019 Jun; 33(3):355-364. PubMed ID: 30332506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia.
    Feng Z; Hu Z; Li L; Yu M; Zhang Y; Jing P; Xu X; Wu J; Hu Y; Xu X
    Front Pharmacol; 2024; 15():1298061. PubMed ID: 38327987
    [No Abstract]   [Full Text] [Related]  

  • 19. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150.
    Travis MJ; Busatto GF; Pilowsky LS; Mulligan R; Acton PD; Gacinovic S; Mertens J; Terrière D; Costa DC; Ell PJ; Kerwin RW
    Br J Psychiatry; 1998 Sep; 173():236-41. PubMed ID: 9926100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters.
    Shen HW; Hagino Y; Kobayashi H; Shinohara-Tanaka K; Ikeda K; Yamamoto H; Yamamoto T; Lesch KP; Murphy DL; Hall FS; Uhl GR; Sora I
    Neuropsychopharmacology; 2004 Oct; 29(10):1790-9. PubMed ID: 15226739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.